Fine-mapping analysis identifies thousands of genetic variants contributing to coronary artery disease risk in over one million individuals.
This genome-wide association study (GWAS) fine-mapping analysis utilized summary statistics from over one million individuals of European ancestry to investigate genetic contributions to coronary artery disease (CAD) risk. The primary objective was to estimate the number of genetic variants influencing CAD susceptibility and to prioritize causal candidates through fine-mapping techniques.
The analysis estimated that, on average, 34,000 variants contribute to CAD risk, collectively explaining 3.8% of the total phenotypic variance. Among these, 36 high-confidence variants (posterior inclusion probability > 0.9) were identified, which collectively explained 13.6% of the genetic variance. Additionally, 17,150 variants were prioritized within 581 high-confidence local credible sets, and 195 variants were successfully annotated to specific genes. Downstream pathway analyses implicated 170 variants.
The most influential variants were mapped to the genes PHACTR1, APOE, and LPL, explaining 2.49%, 1.59%, and 1.46% of the genetic variance respectively. The study advances causal understanding of CAD genetics but does not establish experimental proof of causation for specific variants. No adverse events or safety data were reported, as this was a genomic analysis rather than a clinical trial. Key limitations include the reliance on statistical fine-mapping of summary data and the restriction to European ancestry populations. These findings represent genetic associations and prioritized causal variants, not experimentally validated mechanisms, and are not immediately applicable to clinical practice or personalized prevention.